It is expected that relevant national authorities will establish a low-altitude economic regulatory bureau.
①The establishment decision has been approved, and the new bureau is currently in preparation; ② The low-altitude economy set up a dedicated bureau, which can better coordinate resources at all levels to promote industrial development.
Companies with long-term net asset value per share below book value must disclose plans for valuation improvement. State-owned enterprises with net asset value per share below book value are expected to attract incremental funds.
On September 24, the China Securities Regulatory Commission publicly solicited opinions on the 'Guidelines for the Supervision of Listed Companies No. 10 - Market Cap Management (Consultation Draft)'. The guidelines require long-term companies trading below net asset value to disclose their valuation enhancement plans, including targets, deadlines, specific measures, and provide special explanations on the execution of the valuation enhancement plan during the annual performance briefing.
Director of Shandong Jincheng Pharmaceutical Group investigated for suspected stock market manipulation. Q1 performance just turned around according to announcement.
On the evening of today, Shandong Jincheng Pharmaceutical Group announced that its actual controller and chairman, Zhao Yeqing, was under investigation for suspected illegal acts of market manipulation by the China Securities Regulatory Commission. Zhao Yeqing has been the chairman of Jincheng Pharmaceutical Group for 13 years. The last time he appeared in public was at the 3rd China Pharmaceutical and Chemical Conference two days ago. In Q1 of 2024, Jincheng Pharmaceutical Group has shown a good trend of reversing last year's poor performance.
Guizhou Xinbang Pharmaceutical, the company that sold its products at a loss, is going to Hong Kong Stock Exchange.
The Hong Kong Stock Exchange IPO application wave may be imminent. Since May of this year, 22 companies have submitted IPO applications to the Hong Kong Stock Exchange, while the Shanghai and Shenzhen stock exchanges are still in a state of "0 acceptance" during the same period. As a member of the vast army of IPO applications, Taide Pharmaceutical (Zhejiang) Co., Ltd. (referred to as "Taide Pharmaceutical") is launching a sprint towards the Hong Kong Stock Exchange. The application materials showed that Taide Pharmaceutical mainly provides peptide new chemical molecular entity discovery synthesis (CRO) and peptide chemical production, manufacturing and control (CDMO) services to pharmaceutical companies. In the reporting period, Taide Pharmaceutical has already achieved profits. From 2021 to 2023.
Evotec's Partner Zhejiang Jingxin Pharmaceutical Secures Approval From Chinese Medical Authority For Evotec's Insomnia Drug, EVT201
Aurora Mobile Signs Strategic Agreement With Rainbow Digital Commercial